Watch out be­low: Der­mi­ra ax­es ac­ne drug af­ter a cat­a­stroph­ic PhI­II fail­ure

Der­mi­ra set it­self up for one of the big stock $DERM cat­a­lysts of Q1 with its Phase III ac­ne stud­ies for DRM01. And it got knocked down — hard — Mon­day morn­ing as it re­port­ed the late-stage pro­gram had suf­fered a cat­a­stroph­ic fail­ure.

The pri­ma­ry end­points for the two stud­ies showed that the re­sults for the drug close­ly mir­rored the place­bo arm, leav­ing the com­pa­ny with noth­ing to show for it. Der­mi­ra ex­ecs say they will now close down the pro­gram and move on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER